MedPath

ARGENX BV

🇸🇪Sweden
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

145

Active:121
Completed:10

Trial Phases

3 Phases

Phase 1:114
Phase 2:4
Phase 3:11

Drug Approvals

2

NMPA:2

Drug Approvals

Efgartigimod Alfa Injection (Subcutaneous Injection)

Product Name
卫力迦
Approval Number
国药准字SJ20240029
Approval Date
Jul 9, 2024
NMPA

Efgartigimod Alfa Injection

Product Name
卫伟迦
Approval Number
国药准字SJ20230008
Approval Date
Jun 30, 2023
NMPA

Clinical Trials

Distribution across different clinical trial phases (129 trials with phase data)• Click on a phase to view related trials

Phase 1
114 (88.4%)
Phase 3
11 (8.5%)
Phase 2
4 (3.1%)
No trials found

News

No news found
© Copyright 2025. All Rights Reserved by MedPath